← Leaderboards
James D West
University Of Colorado Denver
$14,128,198
Attributed
$16,871,620
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,871,620 · 8
By mechanism
R01$13,322,154 · 5
R42$3,088,886 · 1
R41$256,580 · 1
R21$204,000 · 1
Top collaborators
- John A Rathmacher4 shared
- Michael L. Freeman3 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Raphael A. Nemenoff$15,000,654
- Vitaly Kheyfets$2,451,787
- Brian W Fouty$1,773,427
- Brian D Lowes$1,893,454
- Sue Gu$163,145
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationMouse ModelLungMolecularRegulationCellsEtiologyBmpr2 GenePreventMediatingReceptorSignal TransductionDefectPulmonary Arterial HypertensionMutantPathway InteractionsInflammatoryResponseMitochondriaPulmonary HypertensionClinical TrialsAnimalsAnimal ModelLink
Grant awards (30)
2-HOBA for Treatment of Pulmonary Hypertension$957,913
R42 · FY2025 · HL
The Thromboxane-Prostanoid Receptor in Radiation-Induced Pulmonary Fibrosis$725,891
R01 · FY2025 · CA · contact PI
Activity and therapeutic antagonism of the TP receptor in cardiomyopathy of muscular dystrophy$702,168
R01 · FY2025 · HL · contact PI
2-HOBA for Treatment of Pulmonary Hypertension$957,913
R42 · FY2024 · HL
The Thromboxane-Prostanoid Receptor in Radiation-Induced Pulmonary Fibrosis$689,596
R01 · FY2024 · CA · contact PI
Activity and therapeutic antagonism of the TP receptor in cardiomyopathy of muscular dystrophy$688,125
R01 · FY2024 · HL · contact PI
2-HOBA for Treatment of Pulmonary Hypertension$1,173,060
R42 · FY2023 · HL
The Thromboxane-Prostanoid Receptor in Radiation-Induced Pulmonary Fibrosis$725,891
R01 · FY2023 · CA · contact PI
Activity and therapeutic antagonism of the TP receptor in cardiomyopathy of muscular dystrophy$702,168
R01 · FY2023 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$662,881
R01 · FY2022 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$662,881
R01 · FY2021 · HL · contact PI
2-HOBA for Treatment of Pulmonary Hypertension$256,580
R41 · FY2021 · HL
Interventions Against the Molecular Etiology of BMPR2-induced PAH$662,881
R01 · FY2020 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$662,881
R01 · FY2019 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$494,753
R01 · FY2018 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$494,754
R01 · FY2017 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$376,811
R01 · FY2016 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$114,874
R01 · FY2016 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$543,969
R01 · FY2015 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$477,622
R01 · FY2013 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$501,704
R01 · FY2012 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$501,704
R01 · FY2011 · HL · contact PI
Role of p38 and p42/44 MAPK in Pulmonary Arterial Hypertension$383,750
R01 · FY2011 · HL · contact PI
Interventions Against the Molecular Etiology of BMPR2-induced PAH$503,522
R01 · FY2010 · HL · contact PI
Role of p38 and p42/44 MAPK in Pulmonary Arterial Hypertension$383,750
R01 · FY2010 · HL · contact PI
Role of p38 and p42/44 MAPK in Pulmonary Arterial Hypertension$383,750
R01 · FY2009 · HL · contact PI
Role of p38 and p42/44 MAPK in Pulmonary Arterial Hypertension$383,750
R01 · FY2008 · HL · contact PI
Role of p38 and p42/44 MAPK in Pulmonary Arterial Hypertension$383,750
R01 · FY2007 · HL · contact PI
Effects of BMPRII Mutations in Pulmonary Hypertension$508,328
R01 · FY2005 · HL
Genetics of Pulmonary Hypertension in Mice$204,000
R21 · FY2005 · HL